Intravenous injection of monoclonal anti-IL-9 antibodies was proven effective in ameliorating disease outcomes in the Eμ-TCL1/p66Shc−/− mouse model of aggressive CLL [15], paving the way to further pre-clinical studies. The gene discussed is IL9; the disease is B-cell chronic lymphocytic leukemia.